Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (171-180 of 337) with videos related to

Pageof 34
Sort By:
Mechanisms of Ageing and Development|July 13, 2004
Retinoic acid receptor alpha expression and cutaneous ageingRachel E B Watson, J Arjuna Ratnayaka, Rebecca C C Brooke, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
The Journal of Investigative Dermatology|March 6, 2015
Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research DatalinkRosa Parisi, Martin K Rutter, Mark Lunt, et al.
Experimental Dermatology|April 15, 2018
Lipidomics for translational skin research: A primer for the uninitiatedAlexandra C Kendall, Marta M Koszyczarek, Emrys A Jones, et al.
The Journal of Investigative Dermatology|March 9, 2007
Increased blood levels of IgG reactive with secreted Streptococcus pyogenes proteins in chronic plaque psoriasisRana G El-Rachkidy, Jonathan M Hales, Primrose P E Freestone, et al.
Acta Dermato-Venereologica|December 24, 2015
Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and StructureAndrea K Murray, Tonia L Moore, Joanne B Manning, et al.
The British Journal of Dermatology|April 30, 2023
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trialRichard B Warren, Adam Reich, Andrzej Kaszuba, et al.
Pageof 34

Showing results (171-180 of 337) with videos related to

Sort By:
Pageof 34
Mechanisms of Ageing and Development|July 13, 2004
Retinoic acid receptor alpha expression and cutaneous ageingRachel E B Watson, J Arjuna Ratnayaka, Rebecca C C Brooke, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
The Journal of Investigative Dermatology|March 6, 2015
Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research DatalinkRosa Parisi, Martin K Rutter, Mark Lunt, et al.
Experimental Dermatology|April 15, 2018
Lipidomics for translational skin research: A primer for the uninitiatedAlexandra C Kendall, Marta M Koszyczarek, Emrys A Jones, et al.
The Journal of Investigative Dermatology|March 9, 2007
Increased blood levels of IgG reactive with secreted Streptococcus pyogenes proteins in chronic plaque psoriasisRana G El-Rachkidy, Jonathan M Hales, Primrose P E Freestone, et al.
Acta Dermato-Venereologica|December 24, 2015
Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and StructureAndrea K Murray, Tonia L Moore, Joanne B Manning, et al.
The British Journal of Dermatology|April 30, 2023
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trialRichard B Warren, Adam Reich, Andrzej Kaszuba, et al.
Pageof 34